Germany-based medical startup, Inovedis, recently secured €3.78M in a Series A funding round. This funding aims to expedite the commercialisation of the SINEFIX surgical system.
About Inovedis
Founded in 2019 by trauma and orthopaedic surgeon Dr Stefan Welte and entrepreneur Lukas Floess, Inovedis is headquartered in Albstadt. The company strives to optimise patient care, aiming to reduce surgical intervention complexity, cost, and time.
Investors and purpose
This funding round witnessed participation from Inovedis’ initial seed investors such as High-Tech Gründerfonds, MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg, Volksbank Albstadt ChancenKapital, and Start-UP BW Innovation Fonds. Notably, Renolit SE, SINEFIX’s current manufacturer, also made an initial investment.
Inovedis plans to use these funds to launch the SINEFIX implant system in the US. Additionally, they aim to sponsor a German clinical study to gather data essential for CE marking and European sales expansion.
SINEFIX: addressing a medical challenge
Inovedis identified a gap in treating rotator cuff lesions (RCL) with arthroscopic treatment dependent on suture anchor technology. Their solution, SINEFIX, is designed to enhance surgical efficiency, respect the patient’s biological state, and bolster intrinsic healing potential by ensuring flat tendon and bone contact.
Currently, SINEFIX awaits FDA approval in the US. Meanwhile, under Prof Dr Philip Kasten’s leadership, the European approval trial for SINEFIX has commenced. Prof Dr Kasten is an expert at the Orthopaedic Surgery Center in Tuebingen, Germany.
How SINEFIX functions
The SINEFIX implant system facilitates the refixation of the rotator cuff tendon to bone through a simplified surgical technique. This minimally invasive method includes an expansive instrument range, minimising instrumentation and eradicating intricate suture management and knot tying.
Dr Kasten notes that 70% of patients possess a partial thickness rotator cuff tear, and only 28% have a full one. SINEFIX provides an effective treatment for minor and partial tears. Unlike other treatments, there’s no need to detach the tendon before reattachment, filling a vital treatment void.
Dr Welte asserts that the SINEFIX surgical method could reduce procedure duration and potentially enhance tendon-to-bone fixation, using fewer implants. The increased pull-out forces, higher than double row fixation with suture anchors, enable its use in porous bones. This procedure is intended to lower surgical error risks, substantially cutting down surgery time, leading to clinical surgery cost and time savings.
—
Is your company currently looking to expand and build a team of superstars? We can help with that. Speak to a PL Talents recruitment expert today.